CYP19A1 and breast carcinoma: Aromatase inhibitors (AIs) have been used as the first choice of adjuvant endocrine therapy for postmenopausal women over the last 15 years since they are more effective than tamoxifen for postmenopausal breast cancer, and AI prescriptions account for 64% of endocrine therapy among women with invasive breast cancer [1].